

August 27, 2018



CytoDyn, Inc.’s President and CEO, Nader Pourhassan, Ph.D., Discusses Company Research with Everett Jolly on Uptick Newswire’s “Stock Day” Podcast

PHOENIX, Aug. 27, 2018 (GLOBE NEWSWIRE) -- CytoDyn, Inc. (OTCQB:CYDY), (the “Company”) announced President and CEO Nader Pourhassan’s interview on Uptick Newswire’s “Stock Day” Podcast.

Everett Jolly invited a company for the very first time to the “Stock Day” podcast. “With us today is the President and CEO, Nader Pourhassan. Welcome to the show! Your company is involved in the treatment of HIV. Can you tell my listeners more about some of your products?”

Dr. Pourhassan indicated that their main product is a humanized monoclonal antibody, which has shown great results in HIV patients in a human clinical trial. It has fast-track designation with the FDA, with the possibility of accelerated approval hopefully in early 2019. With one complete trial which was pivotal, the Company hit their end point.

There is currently no cure for HIV, so product development and improvements are ongoing. CytoDyn plans to work on an at-home, self-injectable, once-a-week antibody. He pointed out that this would improve the patient’s quality of life and that there’s currently nothing similarly available. Toxicity and side effects are always a concern and patients want to have something simpler, that is less of a burden. That’s what CytoDyn’s plan intends to address.

There was a brief discussion of a letter of intent and acquisition of a company dealing with exciting advanced cancer treatment that could shift the whole paradigm of treatment. This ultimately led to the Company hiring a new Board member, Michael Klump.

For more information about the Company’s research and financial details, listen to the full interview at the link below:

<https://upticknewswire.com/featured-interview-ceo-dr-nader-pourhassan-of-cytodyn-inc-otcqb-cydy/>

About CytoDyn, Inc.

CytoDyn, Inc. is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn’s lead product candidate, PRO 140, has the potential to drive groundbreaking advancements in

developing the next generation of HIV treatments.

CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus infection. Its product pipeline includes PRO 140, CytoFeline, and Cytolin. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.

Contact:

CytoDyn, Inc.
1111 Main Street
Suite 660
Vancouver, WA 98660
(360) 980-8524
<https://www.cytodyn.com/>
info@cytodyn.com

Safe Harbor Act and Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

About Uptick Newswire and the “Stock Day” Podcast:

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at <https://investorshangout.com/>

SOURCE:

Uptick Newswire

<https://upticknewswire.com/>



Source: CytoDyn, Inc.